Elicio Therapeutics

Elicio Therapeutics

Yahoo Finance • 5 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX).  Such investors are advised to contact Danielle Peyton at n... Full story

Yahoo Finance • 11 days ago

Top Biotech Gainers: QURE Rallies On AMT-130 Update, LNAI On Track, FTH Eyes Q4 Data, ELTX On Watch

(RTTNews) - Today's top gainers included uniQure, which rallied after the FDA softened its stance on the company's investigational gene therapy; Elicio Therapeutics, following encouraging treatment responses from its cancer vaccine in panc... Full story

Yahoo Finance • 13 days ago

Stocks Settle Sharply Higher as US-Iran Peace Deal Spurs Optimism

The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.65%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.92%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +3.06%.  June E-mini S&P futures (ESM26) rose +1.68%, and June E-m... Full story

Yahoo Finance • 13 days ago

Stocks Rally as US-Iran Peace Deal Sinks Oil and Bond Yields

The S&P 500 Index ($SPX) (SPY) today is up +1.67%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.24%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +2.79%.  June E-mini S&P futures (ESM26) are up +1.72%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • 13 days ago

Stocks Soar on US-Iran Peace Agreement

The S&P 500 Index ($SPX) (SPY) today is up +1.62%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.09%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +2.73%.  June E-mini S&P futures (ESM26) are up +1.61%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • 13 days ago

ELTX INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Elicio Therapeutics, Inc.

ATLANTA, June 15, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Elicio Therapeutics, Inc. (“Elicio” or the “Company”) (NASDAQ: ELTX) complied with federal securities laws. On June 15, 2026, Elicio announced that... Full story

Yahoo Finance • 14 days ago

Pre-Market Movers: BYAH, LXEO, ELTX Swing Big

(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Price swings ahead of the opening bell are being driven by clinical trial and regulatory updates, as well as trial endpoint misses. In the Green - Prem... Full story

Yahoo Finance • 4 months ago

Elicio Therapeutics reports FY GAAP EPS of -$2.58

* Elicio Therapeutics press release [https://seekingalpha.com/pr/20435956-elicio-therapeutics-reports-full-year-2025-financial-results-and-provides-corporate-updates] (ELTX [https://seekingalpha.com/symbol/ELTX]): FY GAAP EPS of -$2.58.... Full story

Yahoo Finance • 7 months ago

Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today annou... Full story

Yahoo Finance • 7 months ago

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), fewer disease progressions and deaths than projected have been observed as of November 6, 2025. Based on 2:1 randomiz... Full story

Yahoo Finance • 8 months ago

KRAS Inhibitors Market to Witness Explosive Growth at a CAGR of 35% During the Forecast Period (2025–2034) Amid Expanding Therapeutic Landscape | DelveInsight

DelveInsight Business Research LLP The KRAS inhibitors market is expected to experience substantial growth, driven by rising cancer incidence, improved treatment access, and a robust pipeline including Olomorasib (Eli Lilly), MK-1084 (Mer... Full story

Yahoo Finance • 9 months ago

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor (“CPI”) in the neoadjuvant setting Trial is anticipated to begin enrolling in H1’2026 BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeut... Full story

Yahoo Finance • 9 months ago

Elicio Therapeutics Reports Inducement Grants

BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today anno... Full story

Yahoo Finance • 11 months ago

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

At extended median follow-up of 19.7 months, median overall survival (“OS”) increased from 16.33 to 28.94 months Clinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS (“mKRAS”) induced by ELI-00277% re... Full story

Yahoo Finance • 11 months ago

Elicio (ELTX) Q2 Loss Beats Estimates

Key Points Elicio Therapeutics (NASDAQ:ELTX) reported a net loss per share of $0.66 (GAAP) for the second quarter, beating the analyst estimate of $(0.69) (GAAP). Research and development (R&D) expenses (GAAP) decreased 14.6% year-over-ye... Full story

Yahoo Finance • 11 months ago

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings

Syringe and red cross by Stadratte via iStock Cancer remains one of the most relentless challenges in modern medicine. In 2025, over 2 million new cancer cases are expected to be diagnosed in the United States. More than 618,000 people wi... Full story

Yahoo Finance • last year

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

BOSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today annou... Full story

Yahoo Finance • last year

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, to... Full story

Yahoo Finance • last year

Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025.In this article, we are going to take a look at where Elicio Therapeutics Inc (NASDAQ:ELTX) stands against the other healthcare stocks. The... Full story

Yahoo Finance • last year

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis Phase 2 randomized study of ELI-002 fully enrolled, with formal int... Full story